Comparative Pharmacology
Head-to-head clinical analysis: EFFEXOR versus FETZIMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFEXOR versus FETZIMA.
EFFEXOR vs FETZIMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits serotonin and norepinephrine reuptake by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET), increasing extracellular concentrations of serotonin and norepinephrine in the CNS.
Fetzima (levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine, with approximately 2-fold higher potency for norepinephrine reuptake inhibition, which enhances neurotransmission in the central nervous system.
Initial: 75 mg/day PO in 2-3 divided doses; may increase by 75 mg/day increments at intervals of 4 days or more; max 375 mg/day. Extended-release: initial 37.5-75 mg PO once daily, titrate up to max 225 mg/day.
20 mg orally once daily for 2 days, then 40 mg once daily for 2 days, then 80 mg once daily for 2 days, then 120 mg once daily; maximum dose 120 mg/day.
None Documented
None Documented
Venlafaxine: ~5 ± 2 hours; ODV (active metabolite): ~11 ± 2 hours. At steady state, effective half-life for total active moiety (venlafaxine + ODV) is ~11 hours. Clinical context: requires twice-daily dosing for immediate-release; extended-release formulations allow once-daily dosing.
Terminal elimination half-life is approximately 12 hours for levomilnacipran; at steady state, half-life supports once-daily dosing without extensive accumulation.
Primarily renal (≈87% of dose eliminated in urine), with approximately 29% as unchanged venlafaxine, 26% as unconjugated O-desmethylvenlafaxine (ODV), and the remainder as other metabolites. Fecal elimination accounts for <10%. Biliary excretion is negligible.
Primarily renal (approximately 65% as unchanged levomilnacipran and 25% as N-desmethyllevomilnacipran); fecal excretion accounts for ~8%.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant